Media

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Vicore Pharma – Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis

Gesynta Pharma receives UK approval for a Phase 2 trial of vipoglanstat in endometriosis

Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD)

Intervacc appoints Anna-Carin Lagerlöf as Sales and Marketing Director

Vicore Announces Presentations at the European Respiratory Society Congress 2025

Oncopeptides’ rights issue oversubscribed to approximately 157 percent 

Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer

Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating Officer

Oncopeptides – New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting